Skip to content
Sign in
Health · South Asia

Tamil Nadu launches Kadayanallur pilot to assess Takeda’s Qdenga dengue vaccine

The Kadayanallur study will generate local evidence on Qdenga’s performance, complementing the WHO’s 2024 prequalification of the vaccine and helping clarify its potential role in dengue prevention.

AI-assisted synthesis · Based on 3 outlets' reporting · Article text read from 1 of 3 outletsHow it's made

View timeline · 8 entries
3 outletsLatest reporting 2 min read
Coverage: Center OnlyL 0 · C 3 · R 0
Updat3 graphic: India
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • Tamil Nadu is studying the effectiveness of a dengue vaccine in Kadayanallur (per NDTV, The Hindu, oneindia.com).
  • The Kadayanallur pilot is focused on Qdenga, a dengue vaccine developed by Takeda (per NDTV, oneindia.com).
  • Tamil Nadu Health Minister K.G. Arunraj announced the initiative on October 17, 2026 (per NDTV).
  • The study is intended to help inform wider vaccination plans (per NDTV).
  • Qdenga is also known as TAK-003 and is a live-attenuated vaccine designed to protect against DENV-1, DENV-2, DENV-3 and DENV-4 (per NDTV).
  • The WHO granted Qdenga prequalification in May 2024 and recommends it for children aged six to 16 in settings with high dengue burden and transmission intensity (per NDTV).

The brief

Tamil Nadu has begun a pilot in Kadayanallur to assess Qdenga, a dengue vaccine developed by Takeda. The Hindu’s headline also reports that the state will study the vaccine’s effectiveness there. Tamil Nadu Health Minister K.G. Arunraj announced the initiative on October 17, 2026, according to NDTV. The study is intended to inform wider vaccination plans.

The vaccine is also known as TAK-003. NDTV describes it as a live-attenuated vaccine, containing weakened versions of dengue virus and designed to protect against all four serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. The Kadayanallur initiative is a pilot to assess effectiveness; the account does not give a study duration or report findings from the assessment.

NDTV reports that the World Health Organization granted Qdenga prequalification in May 2024. The WHO recommends its use for children aged six to 16 in settings with high dengue burden and transmission intensity. The recommendation is specifically directed to that age group and those settings.

Arunraj’s announcement reportedly said India’s Central Drugs Standard Control Organisation had approved Qdenga for people aged four to 60. That age range differs from the WHO’s stated recommendation, which focuses on children aged six to 16 in high-transmission settings. The account does not detail the terms or conditions of the Indian approval.

Arunraj cited estimates of 80% protection following the two-dose schedule. The account presents this figure as an estimate cited by the minister, rather than as a result from the Kadayanallur pilot. It does not provide the study or other evidence behind the estimate. NDTV also says experts stressed that mosquito control remains essential alongside vaccination.

The account therefore describes the pilot as part of a wider approach in which vaccination does not replace mosquito control. Oneindia’s headline characterizes the Kadayanallur pilot as a possible turning point, but supplies no further detail about that description.

The central reported next step is the local assessment, which Tamil Nadu says will help guide wider vaccination plans.

Why it matters

  • The pilot assesses Qdenga in Kadayanallur, with Tamil Nadu saying the findings will inform wider vaccination plans.
  • The vaccine is designed to cover four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4.
  • The stated Indian approval covers people aged four to 60, while the WHO recommendation cited applies to children aged six to 16 in high-transmission settings.
  • Experts cited by NDTV say mosquito control remains essential alongside vaccination.

What to watch next

  • Whether Tamil Nadu reports findings from the Kadayanallur effectiveness study.
  • How Tamil Nadu uses the study to inform wider vaccination plans.
  • Whether officials provide details about the Central Drugs Standard Control Organisation approval for ages four to 60.
  • Whether Arunraj or other officials provide evidence supporting the cited estimate of 80% protection after two doses.

How it's being covered

Coverage analysisShow details
3 source articles · 3 unique outlets
Outlet political mix: Center Only· 3 Center
Where the outlets are based: Asia 67% · Unknown 33%
Outlet political mix
Center Only
Left
Center
Right
0 outlets
3 outlets
0 outlets
The marker shows coverage balance: each unique outlet counts once.
Geography
Where the outlets covering this story are based.
3 unique outletsDominant coverage: Asia
Coverage imbalance
  • Coverage is currently concentrated among Center-rated outlets (3 of 3 rated sources); comparatively few Left or Right-rated outlets have published on the event.
How we measure coverage

How outlets' accounts compare

Updat3 does not yet have enough full reports to compare how outlets framed this story.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. Takeda’s TIDES phase 3 trial, launched in 2016, tested TAK-003 among children and adolescents in dengue-endemic countries.
    Background · from our historical context
  2. In November 2017, Sanofi reported that Dengvaxia could increase the risk of severe dengue in people who had not previously been infected.
    Background · from our historical context
  3. In April 2018, WHO’s Strategic Advisory Group of Experts recommended that Dengvaxia be used only where vaccination could be limited to people with evidence of a prior dengue infection.
    Background · from our historical context
  4. The European Commission had authorized it for use in the European Union in December 2022, following review by the European Medicines Agency.
    Background · from our historical context
  5. WHO recommended TAK-003 for children aged six to 16 in settings with high dengue burden and transmission intensity.
    Background · compiled and fact-checked by Updat3
  6. The World Health Organization prequalified Takeda’s dengue vaccine Qdenga, also called TAK-003, in May 2024, after recommending it for children aged six to 16 in places with high dengue burden and transmission.
    Background · from our historical context
  7. WHO’s May 2024 prequalification followed this evidence review.
    Background · from our historical context
  8. Tamil Nadu Health Minister K.G. Arunraj announced the initiative on October 17, 2026.
    Reported in this story's sourcesSource:NDTV

How we got here

The World Health Organization prequalified Takeda’s dengue vaccine Qdenga, also called TAK-003, in May 2024, after recommending it for children aged six to 16 in places with high dengue burden and transmission. Qdenga is a live-attenuated vaccine designed to protect against all four dengue virus serotypes, DENV-1 through DENV-4.

The European Commission had authorized it for use in the European Union in December 2022, following review by the European Medicines Agency. In November 2017, Sanofi reported that Dengvaxia could increase the risk of severe dengue in people who had not previously been infected.

Original sources

1 of 3 articles · Unknown · Show all

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.